Welcome

Longer Gap Between Pfizer Doses Boosts Antibodies, Study Finds

July 22, 2021, 11:01 PM

An interval of eight to 10 weeks between doses of the Covid-19 vaccine developed by Pfizer Inc. and BioNTech SE boosts the effectiveness of the two-shot regimen compared with a shorter interval, a U.K. study found.

“Eight weeks is probably the sweet spot,” in terms of the trade-off between getting as many people fully vaccinated as quickly as possible and allowing the population to produce higher antibody levels, professor Susanna Dunachie, the study lead from the University of Oxford, said at a briefing Thursday.

After inoculating a larger proportion of people than any other major economy, Britain has seen infections ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.